Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association
- Authors
- Wang, Ji-Guang; Kario, Kazuomi; Lau, Titus; Wei, Yong Quek; Park, Chang Gyu; Kim, Cheol Ho; Huang, Jun; Zhang, Weizhong; Li, Yong; Yan, Peter; Hu, Dayi
- Issue Date
- 4월-2011
- Publisher
- NATURE PUBLISHING GROUP
- Keywords
- ambulatory blood pressure; calcium channel blockers; cardiovascular endpoints; randomized controlled trials; target organ damage
- Citation
- HYPERTENSION RESEARCH, v.34, no.4, pp.423 - 430
- Indexed
- SCIE
SCOPUS
- Journal Title
- HYPERTENSION RESEARCH
- Volume
- 34
- Number
- 4
- Start Page
- 423
- End Page
- 430
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/112690
- DOI
- 10.1038/hr.2010.259
- ISSN
- 0916-9636
- Abstract
- Dihydropyridine calcium channel blockers (CCBs) are widely prescribed for the management of hypertension in Eastern Asians. In this study, the Asian Pacific Heart Association's Writing Committee reviewed randomized controlled trials that were conducted in the Eastern Asian region and compared a CCB with an antihypertensive drug of another class. These trials studied ambulatory blood pressure, measures of target organ damage and cardiovascular events as outcomes. Eleven trials studied ambulatory blood pressure in hypertensive patients and demonstrated that the 24-h blood pressure reduction with CCBs was greater than with other classes of antihypertensive drugs, with a weighted mean difference of 5 mm Hg systolic and 3 mm Hg diastolic. Twelve trials that studied various measurements of target organ damage in hypertensive patients produced inconsistent results when comparing CCBs and other classes of antihypertensive drugs. Four trials that studied the hard outcomes had limited power, but confirmed the findings of previous placebo-controlled trials in the region and actively controlled trials in Europe and North America; they suggested that CCBs provided superior protection against stroke and that some agents, such as amlodipine, also provided similar protection against myocardial infarction. In conclusion, CCBs should be recommended as a preferred drug for the management of hypertension in the Eastern Asian region to improve blood pressure control and to confront the aggravating epidemic of stroke and coronary heart disease. Hypertension Research (2011) 34, 423-430; doi:10.1038/hr.2010.259; published online 13 January 2011
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.